$11.740
+0.297 (+2.53%)收盤時
TLX 同業比較
In the context of the broader market, TLX competes directly with industry leaders such as CRSP and DNTH. With a market capitalization of $3.84B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against CRSP's 100.00% and DNTH's 100.00%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.
Telix Pharmaceuticals Ltd 財務表現
Telix reported a revenue of $247 million for Q2 2026, a 21% increase year-over-year, and expects to exceed $1 billion in revenue for the full year 2026, indicating strong growth potential.
Financials
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。